Kornimate/medical-research-clean huggingface dataset:
tissue engineering microtia auricular reconstruction: in vitro and in vivo studies

Conditions: Microtia

Summary: platelet-rich plasma (prp) has mixed growth factors such as tgf-ß1 and tgf-ß2, vascular epithelial growth factor (vegf), platelet-derived growth factor (pdgf), and insulin-like growth factor (igf). these growth factors appear to play an important role in wound healing and are assumed as promoters of tissue regeneration. moreover, prp was used as injectable scaffold seeded with chondrocytes to regenerate cartilage. in their previous study, the investigators concluded that growth factors in prp can effectively react as a growth factor cocktail to induce human nucleus pulposus proliferation and differentiation, and also promote tissue-engineered nucleus pulposus formation. the investigators also have a hypothesis that prp can promote tissue-engineered microtia auricular cartilage formation. tgf- ß1 exists in the highest concentration and is more important among all of the growth factors released from prp. so tgf- ß1 can be used as the core ingredient and the indicator for applying prp in these studies. the aim of this study was to compare the histological and biochemical character of microtia chondrocytes treated with and without prp.


Eligibility criteria:
inclusion criteria: * microtia patient exclusion criteria: * non microtia patient

Keywords: tissue engineering
early versus late closure of preventive ileostomy

Conditions: Ileostomy, Rectal Cancer

Summary: the study is designed and performed as a prospective randomized controlled single-center study. patients who underwent rectal resection with preventive ileostomy due to rectal cancer will be included. the study investigates the effect of reversing a temporary ileostomy after 30 vs 90 days.


Eligibility criteria:
inclusion criteria: * patients with temporary ileostomy after rectal resection for rectal cancer * patients willing to participate in the study exclusion criteria: * anastomosis insufficiency detected clinically or radiologically. * patients, who are physically and mentally unfit to undergo surgery or to be followed-up
impact of maternal iron status on neonatal iron status and auditory brainstem response in the newborn

Conditions: Anemia

Summary: this study aims to determine how maternal fe status influences placental and neonatal fe status in pregnant adolescents and to assess the impact of the fe endowment of birth on functional outcomes as assessed by auditory brainstem responses within 48 h of delivery in neonates born to these adolescents.


Eligibility criteria:
inclusion criteria: * adolescents (ages 11-18 y) and their newborns will be eligible to participate if the adolescent is carrying a singleton pregnancy, does not have any preexisting medical complications (such as hiv-infection, eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis). exclusion criteria: * individuals with pregnancy induced hypertension or elevated diastolic blood pressure (\>110) will not be eligible to participate in the study. in addition, adolescents who have been previously treated for lead exposure, or those that have been identified as having elevated blood lead concentrations during childhood, will be excluded from the study. * data from infants that experience perinatal asphyxia, pathologic neonatal hyperbilirubinemia, respiratory disease, antibiotic therapy (aminoglycosides), cns infection, sepsis, congenital or middle or external ear lesions, craniofacial anomalies, chromosomal disorders, torch (toxoplasmosis, other infections, rubella, cytomegalovirus infection and herpes simplex infection) or those that were clinically unstable with the first 48 h post-delivery will be excluded from abr studies. infants born to mothers with positive drug abuse screens at delivery will also be excluded from further study (these screens are automatically run among this age group). infants that are identified with hearing deficits at birth using the oae screening will be excluded from the abr measures.

Keywords: iron pregnancy adolescents auditory brainstem responses anemia neonate
effect of the use of simulation (video) on the oral hygiene

Conditions: "Hematologic Diseases"

Summary: the care of the oral cavity is an important way to prevent local and systemic infections. this study aimed to: evaluate the use of video as a teaching strategy of oral hygiene for patients undergoing chemotherapy. the methodological design used was quasi-experimental before-after intervention. the sample consisted of 23 subjects who performed the technique of oral hygiene before and after watching an educational video. to do so was given a kit with a toothbrush with soft bristles, toothpaste with low abrasivity, mouthwash or product to mouthwash and dental floss for oral hygiene. for data analysis we applied the parametric test t "student" paired.

general purpose evaluating the use of video as a teaching strategy of oral hygiene for patients undergoing chemotherapy. specific objectives assess the steps taken by the subjects to oral hygiene before (initial performance) and after (final performance) exposure to an educational video on oral hygiene; to investigate the effect of an educational video on oral hygiene in this clientele; identify patient acceptance of the teaching method employed. methods and procedures delineation the research was quasi-experimental in nature, before-after intervention (the intervention in this study was the teaching learning strategy employed used an educational video on oral hygiene.) patients will be evaluated individually, before and after exposure to video. it is not foreseen monitoring at other times.

Eligibility criteria:
inclusion criteria: * physical conditions for self-care during the oral hygiene; * score less than or equal to three according to scale performance general condition was drafted and approved by the american eastern cooperative oncology group (ecog) * accept oral diet * lack of nasal catheter or probe nasogastric and nasoenteric * present platelet counts \> 20,000 mm3 * neutrophils \> 1,000 mm3 * absence of pathologies or buccal devices which prevent attainment the procedure * the presence of teeth

Keywords: nursing simulation education
double and single intrauterine insemination in controlled ovarian stimulation (coh) cycles with multifollicular development

Conditions: Infertility

Summary: our hypothesis is double insemination will improve pregnancy rates in coh cycles with more than one dominant follicles (\>16mm).

metaanalysis for the effects of double iui demonstrates that effects of this procedure is not different from single iui. it is known that nearly 25% of coh cycles is evident by monofollicular development.for this reason it is possible that this monofollicular cycles in the studies could decrease the effects of double iui. inclusion criteria: 1. patients with unexplained infertility or mild male factor infertility whom admitted to the coh+iui programme in our infertility unit. 2. female age \<37 years old. 3. baseline fsh \<12 miu/l 4. total antral follicle count\>6 5. during the first three cycles of coh+iui 6. minimum 2 follicles \>16 mm at the day of hcg. primary outcome: ongoing pregnancy rates secondary outcomes: the effects of different coh regimens (cc,fsh,cc+fsh)on the outcomes.

Eligibility criteria:
inclusion criteria: * unexplained and mild male factor infertile patients * minimum 2 follicles \>16 mm at the day of hcg * first 3 cycles exclusion criteria: * basal fsh \>12 miu/l * total antral follicle count\<6 * severe male factor infertility

Keywords: double iui intrauterine insemination unexplained infertility
evaluation of an education program to increase knowledge and participation in clinical trials among racial/ethnic and rural populations

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial evaluates a culturally tailored educational outreach intervention for increasing clinical trial knowledge, referral, and participation among racial/ethnic minority and rural populations. clinical trials are research studies that involve people. through clinical trials, researchers are able to determine whether new treatments are safe and effective and work better than current treatments. clinical trials can also help find new ways to prevent and detect cancer and improve the quality of life for people during and after treatment. recruitment and retention of underrepresented groups in clinical trials remains a challenge. racial and ethnic minority groups bear a disproportionate burden of cancer compared with other groups yet these populations continue to be underrepresented in clinical trials. this clinical trial uses community health educators (ches) to facilitate individual and group education sessions to improve knowledge of what constitutes a clinical trial, the value of participating in clinical trials, and why it is important for racial/ethnic minorities to participate in clinical trials.

primary objective: i. to implement culturally tailored educational outreach activities with the goal of increasing clinical trial (ct) knowledge, referral and participation among racial/ethnic and rural populations. outline: participants attend an educational session with ches and receive educational materials on study.

Eligibility criteria:
inclusion criteria: * adult males and females 18 years of age and older from ohio * will not let anyone who is not cognitively able to give voluntary informed consent take part in the education sessions
real-world outcomes in relapsed/refractory multiple myeloma patients treated, or eligible for treatment, with idecabtagene vicleucel

Conditions: Multiple Myeloma

Summary: the purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in france with relapsed/refractory multiple myeloma (rrmm) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. this study will use both prospective and retrospective data from the descar-t registry database.


Eligibility criteria:
inclusion criteria: * patients with rrmm registered in the descar-t registry and eligible for treatment or treated with idecabtagene vicleucel exclusion criteria: * not registered with the social security in france
comparison of hand functions and wrist proprioception in patients with and without psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: the purpose of this study is to assess hand functions and wrist joint position sense in patients with and without psa.

in this study, 54 patients (18 of them ra, 18 of them psa and, 18 of them asymptomatic healthy group) were included. the patient group was selected from the patients who came to the izmir katip celebi university ataturk training and research hospital rheumatology outpatient clinic for routine control. participants were matched according to age and gender. it was recorded demographic and clinical data. grip and pinch strengths were evaluated within the scope of hand function evaluation. wrist joint position sense was evaluated along with hand functions.

Eligibility criteria:
inclusion criteria: * to be diagnosed according to caspar or acr/ eular 2010 criteria for patient groups * taking regular medication for patient groups, * have complaints related to hand / wrist joints for patients groups, * have no complaints related to upper extremity for asymptomatic healthy group. * have any rheumatologic disease and oa diagnosed according to traditional criteria exclusion criteria: * finger infection and / or finger amputation, * using orthoses, * to report a diagnosis of neurological disease, * to report a history of trauma or surgery involving the upper extremity, * to report a psychiatric and / or cognitive problem

Keywords: psoriatic arthritis, hand function, wrist proprioception.
study of a pandemic influenza vaccine in elderly participants

Conditions: Influenza

Summary: the world health organisation has warned that an influenza pandemic is inevitable. the avian influenza h5n1 virus strain is one of the leading candidates to cause the next influenza pandemic. the elderly are likely to be a special target group for vaccination; therefore, this study will test the safety and immunogenicity of a h5n1 pandemic influenza vaccine in a healthy elderly population.


Eligibility criteria:
inclusion criteria: * healthy male and female participants exclusion criteria: * history of clinically significant medical conditions * history of guillain-barre syndrome or active neurological disease * resident of nursing home or long-term care facility

Keywords: pandemic influenza prevention vaccine prevention of pandemic influenza
characterization of human memory immune responses to prior yellow fever vaccination

Conditions: Yellow Fever Vaccine

Summary: the objective of this study is to study immune memory generated against the yellow fever (yfv) vaccine in participants who have previously received the vaccine. volunteers will not receive vaccine shots; only immune responses to previous yellow fever vaccination will be studied. the study involves one or multiple blood draws.

the goal of this study is to characterize immune memory in humans who have previously received yellow fever vaccine. the project is designed to study the magnitude and persistence of both humoral, and cell-mediated immune memory generated post-vaccination. since aging has an effect on the immune system (eg. decreased thymic output, replacement of hematopoietic cells in the bone marrow with adipocytes), the researchers will analyze the young adults (aged 18-45 years) and the older vaccinees (55 years or older) in separate groups. the specific aims of the study are to: * determine the phenotypic and functional characterization of memory t cell responses to yellow fever vaccination * determine neutralizing antibody titer after yellow fever vaccination

Eligibility criteria:
inclusion criteria: * able to understand and give informed consent * age 18-45 years (group 1) or 55 years and above (group 2) at the time of yellow fever vaccination * documentation (international certificate of vaccination (yellow card) or medical record) indicating receipt of yellow fever vaccine. exclusion criteria: * recipient of any vaccines within 30 days before the study visit (not applicable to older adults) * history of a progressive and severe chronic medical condition resulting in impaired immunity (such as diabetes, kidney or liver dysfunction) * required use of immunosuppressive medications * reporting hiv, hepatitis b (surface antigen positive) or hepatitis c infections (antibody positive) on the medical/health history form * recipient of a blood product or immune globulin product within 42 days of study visit * reporting pregnancy
.exercise and follow-up after a mastectomy

Conditions: Mastectomy; Lymphedema

Summary: a randomized control trial (rct) on the effect of education and exercise on women after a mastectomy found positive results in range of motion of the affected shoulder and quality of life in the intervention group.

background: breast cancer ranks highest in incidence and mortality among females and ranks second when both genders are combined. lebanon has the second highest rate of breast cancer worldwide for the 35-39 age group and the highest in the 40-49 age group. mastectomy often results in deceased shoulder and arm mobility, and decreased quality of life. objective: the objective of this study was to assess the effect of an educational program of therapeutic exercises on the quality of life and functional ability in women after a mastectomy methods: sixty women undergoing mastectomy were randomly assigned to an intervention and control group. the intervention group received extensive teaching pre-surgery education as well as training on therapeutic exercises. follow up phone calls to the intervention group were made to assure that the exercises were being done. both groups were visited at home at four and eight to obtain the outcome variables. the breast cancer patient version was used to asses quality of life and the "goniometer" was used to assess the range of motion of the affected shoulder.

Eligibility criteria:
inclusion criteria included: * women between 35 and 55 years of age * diagnosed with breast cancer * scheduled for modified radical mastectomy. . exclusion criteria included: * women who were pregnant, * not able to communicate, * had co-morbidities that affected their qol

Keywords: mastectomy education exercise
clinical evaluation of two silicone hydrogel daily disposable contact lenses

Conditions: Vision Disorders

Summary: the purpose of this investigation is to evaluate the short-term, clinical performance of two silicone hydrogel daily disposable contact lenses.


Eligibility criteria:
inclusion criteria: * the subject must read, understand, and sign the statement of informed consent and receive a fully executed copy of the form. * the subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. * the subject must be between (and including) 18 and 39 years of age. * the subject must be an adapted wearer of spherical soft contact lenses in both eyes. that is, the subject must wear their habitual lenses at least five (5) days per week and eight (8) hours per day worn for at least 30 days immediately preceding the study. * the subject must have vertex-corrected distance refraction that allows a plano over-refraction with the available contact lens powers of -0.50 to -6.00 diopters (d) in each eye. * the subject must have refractive astigmatism, if present, of less than or equal to 1.00 d in each eye. * the subject must have best corrected visual acuity of 20/25 or better in each eye. exclusion criteria: * currently pregnant or breastfeeding (subjects who become pregnant during the study will be discontinued). * any ocular or systemic allergies or diseases that may interfere with contact lens wear. * any autoimmune disease or use of medication, which may interfere with contact lens wear. * entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia. * any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (prk), laser-assisted in situ keratomileusis (lasik), etc.). * any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the fda classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear. * any ocular infection. * any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. * monovision, multi-focal, toric, or extended wear contact lens correction. * participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment. * history of binocular vision abnormality or strabismus that is likely to affect successful contact lens wear. * any infectious disease (e.g., hepatitis, tuberculosis) or contagious immunosuppressive diseases (e.g., hiv) by self-report.
ecopipam treatment of self-injurious behavior in subjects with lesch-nyhan disease

Conditions: Lesch-Nyhan Disease; Self-injurious Behavior

Summary: the purpose of this research study is to gather scientific information about the effectiveness and safety of the study drug, ecopipam (psyrx 101), for the treatment of self-injurious behaviors when compared with the effectiveness and safety of placebo (inactive substance) in subjects with lesch-nyhan disease.

this study will be done in approximately 6 centers in approximately 4 countries, and approximately 24 subjects will be included. this study is divided into two parts. the first is a double-blinded portion lasting up to 18 weeks in total. the second portion is an optional open-label extension and lasts up to 54 weeks total. the total duration of the study, if you choose to participate in both portions, is anticipated to be up to approximately 78 weeks. the first portion of this study is double-blind and assignment to a treatment group is done randomly. in this study, there are two treatment groups. one group will receive ecopipam for one 6-week period and placebo for two 6-week periods, and the other group will receive ecopipam for two 6-week periods and placebo for one 6-week period. subjects who did not experience any clinically significant side effects during the blinded portion of the study may be eligible to participate in an open-label extension that may last up to 54 weeks.

Eligibility criteria:
inclusion criteria: * subjects must have classic lnd as defined by (a) characteristic clinical syndrome (evidence of overproduction of uric acid, severe generalized dystonia, frequent and persistent self-injurious behavior (sib), and cognitive impairment) and (b) laboratory confirmation for mutation of the hprt gene or severe deficiency of the associated enzyme. * subjects must have a minimum combined score of 20 on the behavior problems inventory (bpi) sib subscales for frequency and severity as assessed by the caregiver. * subjects must have a minimum score of 4 on the physician's global impression (pgi) severity scale. * subject must be ≥ 6 years old. * subjects must weigh \> 10 kg. exclusion criteria: * subjects who are currently treated with medications for seizures. * subjects who are on neuroleptics or dopamine-depleting agents. * subjects with impaired renal function as defined by a serum creatinine \>1.5 mg/dl.

Keywords: lesch nyhan disease self-injury
activity and content of factor viii (fviii) in human plasma: the assessment of a novel immunoassay

Conditions: Hemophilia A

Summary: a novel immuno-assay is being evaluated for the measurement of factor viii. current procedure measures a rate assay which is subject to much artefact. the hypothesis is that the new assay will give a reading of absolute quantities of fviii which will provide a more suitable indicator of fviii content for clotting factor manufacturers, physicians and patients.

remnant samples collected in a clinical laboratory are assayed with the new procedure and compared with the standard functional activated partial thromboplastin time (aptt) assay. a pk study in seven study subjects with hemophilia a is being carried out using five different commercially licensed factor viii concentrates and the blood samples drawn for the pk analysis are being measured for fviii with the novel assay and compared with the standard aptt assay. the concentrates used in the pk studies are also being applied to the two assay systems to determine each product's specific activity.

Eligibility criteria:
inclusion criteria: * adults with hemophilia a * factor viii less that 2% * informed consent signed * absence of an inhibitor exclusion criteria: * history of a high responding inhibitor anemia

Keywords: factor viii hemophilia a assay